Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Feb 22, 2024 1:15pm
122 Views
Post# 35893708

RE:RE:RE:ONCY accumulated deficit (Tax losses applied to a buyout)

RE:RE:RE:ONCY accumulated deficit (Tax losses applied to a buyout)
For accounting purposes the value of the accumulated deficit is really only worth what the acquiring companies tax rate is at which even if at 50% is only then about 250 million and not the total deficit of 450 million as the 250 million would be the realized value in any negotiation.
BTW I am expecting a pr either tomorrow or next week announcing the q4 and year end 2023 as these dates would be in line with previous years announcments for the year end.
The cc would be interesting though depending upon how much the analysts want to push for answers regarding the Blackout.
<< Previous
Bullboard Posts
Next >>